Women injected with the Depo-Provera birth control shot are more than five-times more likely to be diagnosed with a type of brain tumors known as meningioma, according to a recent study. Several ...

Christy Bieber has a JD from UCLA School of Law and began her career as a college instructor and textbook author. She has been writing full time for over a decade with a focus on making financial and ...

Women across the country are taking legal action against Pfizer, the manufacturer of Depo-Provera, alleging that the company failed to warn about the risks of developing meningiomas — generally ...

The Singleton Schreiber Law Firm is seeking individuals who developed potentially life-altering brain tumors as a result of using a popular birth control injection. Singleton Schreiber says the ...

Lawsuits allege that the defendants manufactured, promoted, and sold the prescription drug Depo-Provera without adequately warning of its connection to the development of meningiomas, a type of brain ...

Pfizer is facing a landmark lawsuit in the US brought on behalf of more than 1,000 women who say they developed brain tumors after taking the popular contraceptive injection Depo-Provera. On Monday, ...

-- Global pharmaceutical company Pfizer Inc. (NYSE: PFE), manufacturer of contraceptive injection Depo-Provera (DMPA), is facing a Multidistrict Litigation (MDL No. 3140) in the USA being brought on ...

The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research confirming link between use of Depo-Provera and increased risk of brain tumours ...

Recent research has linked Pfizer’s widely-used Depo-Provera birth control shot to massively increased risk of developing brain tumors — and hundreds of women are suing the pharmaceutical giant over ...

The FDA has approved a label change on the long-acting injectable contraceptive depot medroxyprogesterone acetate, commonly known as Depo-Provera, to warn users of a potential risk of meningioma. The ...

PENSACOLA, Fla.--(BUSINESS WIRE)--A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States ...